SWS Partners Makes New Investment in DexCom, Inc. $DXCM

Key Points

• SWS Partners invested approximately $1.66 million in DexCom, acquiring 19,029 shares of the medical device company in the 2nd quarter.
• Several hedge funds, including Horizon Investments and Wedbush Securities, have increased their holdings in DexCom, indicating a strong institutional interest with 97.75% of the stock owned by institutional investors.
• DexCom's stock has been rated with a consensus of "Moderate Buy", with an average price target of $99.11, despite some recent downgrades by analysts.

SWS Partners bought a new position in DexCom, Inc. (NASDAQ:DXCM - Free Report) in the 2nd quarter, according to its most recent filing with the SEC. The institutional investor bought 19,029 shares of the medical device company's stock, valued at approximately $1,661,000.

Several other hedge funds have also made changes to their positions in the company. Horizon Investments LLC lifted its holdings in shares of DexCom by 2.2% in the 1st quarter. Horizon Investments LLC now owns 5,608 shares of the medical device company's stock worth $383,000 after buying an additional 123 shares during the period. Wedbush Securities Inc. lifted its holdings in shares of DexCom by 1.2% in the 1st quarter. Wedbush Securities Inc. now owns 13,168 shares of the medical device company's stock worth $899,000 after buying an additional 157 shares during the period. Argonautica Private Wealth Management Inc. lifted its holdings in shares of DexCom by 3.2% in the 1st quarter. Argonautica Private Wealth Management Inc. now owns 5,958 shares of the medical device company's stock worth $407,000 after buying an additional 182 shares during the period. Meiji Yasuda Asset Management Co Ltd. lifted its holdings in shares of DexCom by 3.2% in the 1st quarter. Meiji Yasuda Asset Management Co Ltd. now owns 6,019 shares of the medical device company's stock worth $411,000 after buying an additional 187 shares during the period. Finally, Integrated Wealth Concepts LLC lifted its stake in shares of DexCom by 6.3% during the 1st quarter. Integrated Wealth Concepts LLC now owns 3,329 shares of the medical device company's stock worth $227,000 after purchasing an additional 196 shares during the last quarter. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at DexCom

In other news, Director Kyle Malady sold 667 shares of the firm's stock in a transaction dated Friday, September 5th. The stock was sold at an average price of $80.86, for a total value of $53,933.62. Following the completion of the transaction, the director directly owned 22,667 shares in the company, valued at $1,832,853.62. This trade represents a 2.86% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Michael Jon Brown sold 500 shares of the firm's stock in a transaction dated Friday, August 15th. The stock was sold at an average price of $80.29, for a total value of $40,145.00. Following the completion of the transaction, the executive vice president owned 94,102 shares of the company's stock, valued at approximately $7,555,449.58. The trade was a 0.53% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 6,849 shares of company stock valued at $564,733 over the last three months. Company insiders own 0.32% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on DXCM shares. Oppenheimer cut DexCom from an "outperform" rating to a "market perform" rating in a research note on Monday, September 8th. Canaccord Genuity Group restated a "buy" rating and set a $106.00 price objective on shares of DexCom in a research note on Friday, August 1st. Robert W. Baird decreased their price objective on DexCom from $112.00 to $90.00 and set an "outperform" rating for the company in a research note on Friday. Argus started coverage on DexCom in a research note on Thursday, August 21st. They set a "buy" rating and a $100.00 price objective for the company. Finally, Wall Street Zen cut DexCom from a "strong-buy" rating to a "buy" rating in a research note on Sunday, August 10th. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and five have given a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $99.11.

DexCom Trading Down 1.8%

DexCom stock opened at $67.10 on Monday. The stock has a 50-day moving average of $78.27 and a two-hundred day moving average of $78.13. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.35 and a current ratio of 1.52. DexCom, Inc. has a one year low of $57.52 and a one year high of $93.25. The stock has a market cap of $26.31 billion, a PE ratio of 46.60, a price-to-earnings-growth ratio of 1.41 and a beta of 1.48.

DexCom (NASDAQ:DXCM - Get Free Report) last released its quarterly earnings results on Wednesday, July 30th. The medical device company reported $0.48 EPS for the quarter, beating analysts' consensus estimates of $0.45 by $0.03. DexCom had a return on equity of 30.41% and a net margin of 13.29%.The company had revenue of $1.16 billion during the quarter, compared to analysts' expectations of $1.13 billion. During the same period last year, the business posted $0.43 earnings per share. The firm's revenue was up 15.2% compared to the same quarter last year. DexCom has set its FY 2025 guidance at EPS. On average, research analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.